Conference Banner

Emerging Cancer Immunotherapies and Vaccines Conference - Day 2

2013 Archived Content

Day 1 | Day 2 | Following Conference| Download Brochure 


8:55am Chairperson’s Opening Remarks

Anne Moon, Ph.D., Vice President, Product Development, Jennerex

Emerging Cancer Vaccines 

9:00 Challenges in Vaccine Therapy for Hematological Malignancies

David E. AviganDavid E. Avigan, M.D., Associate Professor of Medicine, Harvard Medical School; Director of Hematologic Malignancies, Beth Israel Deaconess Medical Center

We have developed a tumor vaccine in which patient-derived tumor cells are fused with autologous dendritic cells. We have demonstrated that vaccination during post-transplant lymphopoietic reconstitution results in the significant expansion of myeloma-specific T cells. We are now integrating vaccination with reversing critical elements of tumor-mediated immune suppression. This includes vaccination in the context of blockade of the PD-1/PDL-1 pathway.

9:30 Biomarkers Correlative of Clinical Response to Sipuleucel-T

James TragerJames Trager, Ph.D., Vice President, Research, Dendreon

Sipuleucel-T is an autologous cellular immunotherapy approved in the United States for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. A variety of biomarkers, both baseline and pharmacodynamic, are correlative of clinical response to sipuleucel-T. We will discuss the biological interpretations of these markers and in particular their implications in understanding the mechanism of action for sipuleucel-T.

10:00 Augmenting Antigen-Specific CD4+ T Cell Activation in Cancer Immunotherapy

Eric von HofeEric von Hofe, Ph.D., President, Antigen Express

The importance of CD4+ T cells in immunological tolerance and the recognition of foreign pathogens places them at the center of both suppressive and activating anti-cancer immune responses. While CTLA4 and PD-1 checkpoint blockades inhibit immune suppression in a non-specific manner, antigen-specific CD4+ T cell activation may be of greater importance. Strategies for specific CD4+ T cell activation and results from clinical trials of a HER2 peptide modified to increase CD4+ activation (AE37) will be discussed.

10:30 Refreshment Break in Exhibit Hall with Poster Viewing

11:15 Rational Design of Targeted Synthetic Vaccine Particles (tSVP) for Cancer

Takashi Kei Kishimoto, Ph.D., Chief Scientific Officer, Selecta Biosciences, Inc.


11:45 Standardized Immune Monitoring from Frozen Whole Blood and Tissue during Clinical Trials with Novel Epigenetic Immune Cell Markers

Thomas-Oliver Kleen, Ph.D., Executive Vice President, Immune Monitoring, Epiontis GmbH, Germany 

The recent discovery of cell type specific epigenetic markers allows precise and robust quantitation of immune cells in all human samples from only small amounts of blood or tissue. The application of epigenetic assays for Tregs, overall T-cell population, NK cells and further subpopulations will be presented in cancer patients. Epigenetic results reveal the same conclusions as measurements with alternative methods, while showing higher precision. Furthermore, the tests can be applied on both blood and tissue allowing measurements of circulating and tissue-infiltrating immune cells.


12:15 pm Close of Conference

Day 1 | Day 2 | Download Brochure 

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs